Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy

Leukemia Research

Volumn 32, Issue 4, 2008, Pages 643-649

  Jilani, Iman ^a   Kantarjian, Hagop ^b   Gorre, Mercedes ^a   Cortes, Jorge ^b   Ottmann, Oliver ^c   Bhalla, Kapil ^d   Giles, Francis J ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

AKT; BCR ABL; Chronic myeloid leukemia; CrkL; Imatinib; Resistance; STAT5; Survival pathways; Tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; IMATINIB; PROTEIN KINASE B; STAT5 PROTEIN;

ARTICLE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SURVIVAL RATE;

EID: 39049153290     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.08.009     Document Type: Article

References (33)

1. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
2. Brasher B.B., and Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275 (2000) 35631-35637
3. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
4. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
5. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
6. Nardi V., Azam M., and Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11 (2004) 35-43
7. Dai Y., Rahmani M., Corey S.J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279 (2004) 34227-34239
8. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
9. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 64 (2004) 672-677
10. Nieborowska-Skorska M., Wasik M.A., Slupianek A., Salomoni P., Kitamura T., Calabretta B., et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189 (1999) 1229-1242
11. de Groot R.P., Raaijmakers J.A., Lammers J.W., and Koenderman L. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3 (2000) 299-305
12. Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A., Wilson M., Smithgall T.E., et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 21 (2002) 5766-5774
13. Benekli M., Baer M.R., Baumann H., and Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101 (2003) 2940-2954
14. Hemmeryckx B., van Wijk A., Reichert A., Kaartinen V., de Jong R., Pattengale P.K., et al. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res 61 (2001) 1398-1405
15. Sattler M., Salgia R., Okuda K., Uemura N., Durstin M.A., Pisick E., et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 12 (1996) 839-846
16. Skorski T., Bellacosa A., Nieborowska-Skorska M., Majewski M., Martinez R., Choi J.K., et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16 (1997) 6151-6161
17. Tang X., Downes C.P., Whetton A.D., and Owen-Lynch P.J. Role of phosphatidylinositol 3-kinase and specific protein kinase B isoforms in the suppression of apoptosis mediated by the Abelson protein-tyrosine kinase. J Biol Chem 275 (2000) 13142-13148
18. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 (2004) 233-242
19. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15 (2004) 177-182
20. Kharas M.G., and Fruman D.A. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65 (2005) 2047-2053
21. de Groot R.P., Raaijmakers J.A., Lammers J.W., and Koenderman L. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 3 (2000) 299-305
22. Gesbert F., and Griffin J.D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96 (2000) 2269-2276
23. Horita M., Andreu E.J., Benito A., Arbona C., Sanz C., Benet I., et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191 (2000) 977-984
24. Jacobberger J.W., Sramkoski R.M., Frisa P.S., Ye P.P., Gottlieb M.A., Hedley D.W., et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry A 54 (2003) 75-88
25. Detection of chromosome translocation by bead-based flow cytometry. In: Chan H.E., Jilani I., Chang R., and Albitar M. (Eds). Monoclonal antibodies: methods and protocols. Methods in molecular biology (2007), Humana Press, Clifton, NJ Chapter 12
26. Ma W., Kantarjian H., Jilani I., Gorre M., Bhalla K., Ottmann O., et al. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 20 (2006) 1989-1991
27. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
28. Barthe C., Gharbi M.J., Lagarde V., Chollet C., Cony-Makhoul P., Reiffers J., et al. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol 119 (2002) 109-111
29. Ricci C., Scappini B., Divoky V., Gatto S., Onida F., Verstovsek S., et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res 62 (2002) 5995-5998
30. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
31. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99 (2002) 10700-10705
32. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
33. Donato N.J.W.J., Kong L.Y., Meng F., Lee F., and Talpaz M. Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations: a rationale for use of SRC/ABL dual kinase inhibitor-based therapy. Blood (ASH Annual Meeting Abstracts) 106 (2005) Abstract 1087